Hansoh Pharmaceutical Group Company Limited (HKG:3692)
Hong Kong · Delayed Price · Currency is HKD 34.36
-0.98 (-2.77%)
Sep 1, 2026, 4:08 PM HKT
HKG:3692 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 15,899 | 15,028 | 12,261 | 10,104 | 9,382 | 9,935 | |
Revenue Growth | 20.55% | 22.57% | 21.35% | 7.69% | -5.56% | 14.32% |
Cost of Revenue | 1,515 | 1,519 | 1,117 | 1,033 | 870.19 | 870.39 |
Gross Profit | 14,383 | 13,509 | 11,144 | 9,071 | 8,512 | 9,065 |
Selling, General & Admin | 4,762 | 4,736 | 4,508 | 4,241 | 4,148 | 4,371 |
Research & Development | 3,657 | 3,358 | 2,702 | 2,097 | 1,693 | 1,797 |
Other Operating Expenses | 32.26 | 14.3 | 31.98 | 53.9 | 63.73 | 75.91 |
Operating Expenses | 8,451 | 8,108 | 7,242 | 6,392 | 5,905 | 6,244 |
Operating Income | 5,933 | 5,401 | 3,902 | 2,679 | 2,607 | 2,821 |
Interest Expense | -50.14 | -3.16 | -6.69 | -66.68 | -58.14 | -52.82 |
Interest & Investment Income | 1,830 | 1,098 | 1,046 | 1,020 | 331.52 | 253.85 |
Earnings From Equity Investments | - | - | - | -2.12 | -13.86 | - |
Currency Exchange Gain (Loss) | -67.74 | -44.06 | 21.43 | 4.57 | 44.56 | -9.31 |
Other Non Operating Income (Expenses) | 118.91 | 111.08 | 87.35 | 105.25 | 117.17 | 139.34 |
EBT Excluding Unusual Items | 7,764 | 6,563 | 5,050 | 3,741 | 3,029 | 3,152 |
Gain (Loss) on Sale of Investments | 93.67 | -16.71 | 61.27 | 158.22 | 67.58 | 144.49 |
Gain (Loss) on Sale of Assets | 14.49 | 4.3 | 5.72 | 2.1 | 11.24 | 3.94 |
Asset Writedown | - | - | -31.98 | - | - | - |
Other Unusual Items | - | - | - | -134.71 | -159.12 | - |
Pretax Income | 7,872 | 6,551 | 5,085 | 3,766 | 2,948 | 3,300 |
Income Tax Expense | 1,193 | 995.12 | 713.36 | 488.65 | 364.68 | 587.18 |
Net Income | 6,678 | 5,555 | 4,372 | 3,278 | 2,584 | 2,713 |
Net Income to Common | 6,678 | 5,555 | 4,372 | 3,278 | 2,584 | 2,713 |
Net Income Growth | 39.68% | 27.07% | 33.39% | 26.85% | -4.76% | 5.61% |
Shares Outstanding (Basic) | 6,022 | 5,963 | 5,930 | 5,925 | 5,916 | 5,921 |
Shares Outstanding (Diluted) | 6,072 | 5,981 | 5,950 | 6,020 | 5,929 | 5,998 |
Shares Change | 1.96% | 0.52% | -1.16% | 1.52% | -1.14% | 2.04% |
EPS (Basic) | 1.11 | 0.93 | 0.74 | 0.55 | 0.44 | 0.46 |
EPS (Diluted) | 1.11 | 0.93 | 0.73 | 0.52 | 0.44 | 0.44 |
EPS Growth | 37.94% | 26.42% | 40.62% | 19.65% | -1.29% | 1.21% |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Free Cash Flow | - | 6,382 | 3,640 | 2,897 | 2,468 | 2,117 |
Free Cash Flow Per Share | - | 1.07 | 0.61 | 0.48 | 0.42 | 0.35 |
Dividend Per Share | 0.423 | 0.388 | 0.316 | 0.193 | 0.088 | 0.073 |
Dividend Growth | 24.40% | 22.73% | 63.53% | 118.47% | 20.84% | 12.44% |
Gross Margin | 90.47% | 89.89% | 90.89% | 89.78% | 90.72% | 91.24% |
Operating Margin | 37.32% | 35.94% | 31.83% | 26.52% | 27.79% | 28.39% |
Profit Margin | 42.01% | 36.97% | 35.66% | 32.44% | 27.54% | 27.31% |
Free Cash Flow Margin | - | 42.47% | 29.69% | 28.67% | 26.31% | 21.31% |
EBITDA | 6,294 | 5,764 | 4,278 | 3,025 | 2,932 | 3,084 |
EBITDA Margin | 39.59% | 38.35% | 34.89% | 29.94% | 31.25% | 31.04% |
D&A For EBITDA | 360.96 | 362.66 | 375.57 | 345.63 | 324.37 | 263.42 |
EBIT | 5,933 | 5,401 | 3,902 | 2,679 | 2,607 | 2,821 |
EBIT Margin | 37.32% | 35.94% | 31.83% | 26.52% | 27.79% | 28.39% |
Effective Tax Rate | 15.16% | 15.19% | 14.03% | 12.97% | 12.37% | 17.79% |